La Jolla Pharmaceutical (LJPC) COO Acquires $33,220.00 in Stock

La Jolla Pharmaceutical (NASDAQ:LJPC) COO Jennifer Carver acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 27th. The shares were bought at an average price of $33.22 per share, for a total transaction of $33,220.00. Following the completion of the purchase, the chief operating officer now owns 4,500 shares in the company, valued at approximately $149,490. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jennifer Carver also recently made the following trade(s):

  • On Wednesday, December 27th, Jennifer Carver acquired 1,000 shares of La Jolla Pharmaceutical stock. The shares were bought at an average price of $33.22 per share, for a total transaction of $33,220.00.

Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) opened at $32.18 on Monday. The company has a market capitalization of $712.63, a price-to-earnings ratio of -6.31 and a beta of 1.62. La Jolla Pharmaceutical has a 52 week low of $16.71 and a 52 week high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.05. equities analysts expect that La Jolla Pharmaceutical will post -4.91 EPS for the current year.

Several brokerages have weighed in on LJPC. SunTrust Banks set a $65.00 price objective on La Jolla Pharmaceutical and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. BidaskClub upgraded La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. HC Wainwright assumed coverage on La Jolla Pharmaceutical in a research note on Thursday, December 21st. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Chardan Capital reiterated a “buy” rating and set a $90.00 target price on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. La Jolla Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $57.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LJPC. Credit Suisse AG bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter worth $391,000. Schwab Charles Investment Management Inc. raised its stake in shares of La Jolla Pharmaceutical by 30.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 28,079 shares of the biopharmaceutical company’s stock worth $836,000 after purchasing an additional 6,500 shares during the period. Rhumbline Advisers raised its stake in shares of La Jolla Pharmaceutical by 22.1% during the 2nd quarter. Rhumbline Advisers now owns 20,012 shares of the biopharmaceutical company’s stock worth $596,000 after purchasing an additional 3,618 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of La Jolla Pharmaceutical during the 2nd quarter worth $387,000. Finally, Bank of New York Mellon Corp raised its stake in shares of La Jolla Pharmaceutical by 8.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 82,847 shares of the biopharmaceutical company’s stock worth $2,466,000 after purchasing an additional 6,667 shares during the period.

COPYRIGHT VIOLATION WARNING: “La Jolla Pharmaceutical (LJPC) COO Acquires $33,220.00 in Stock” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/01/01/la-jolla-pharmaceutical-ljpc-coo-acquires-33220-00-in-stock.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply